BioSpace News Archive

ABK Biomedical, Inc. has received approval for its Investigational Device Exemption (IDE) application from the U.S. Food and Drug Administration (FDA) to commence a multi-center pivotal clinical study in the United States for its Eye90 microspheres yttrium-90 (Y90) radioembolization therapy.

Bristol Myers Squibb (NYSE: BMY) today announced the acceptance of two late-breaker abstracts for Breyanzi (lisocabtagene maraleucel) studies TRANSCEND FL and TRANSCEND NHL 001 for patients with relapsed or refractory follicular lymphoma (FL) and patients with relapsed or refractory mantle cell lymphoma (MCL), respectively, for presentation at the 2023 International Conference on Malignant Lymphoma (ICML).

Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), and FAR Biotech (FAR), a US-based, AI-driven, computational drug discovery company, have announced a collaboration to advance preclinical programs in neurodegeneration.

Inspira Technologies OXY B.H.N. Ltd., a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer.

A new study published in JAMA Internal Medicine has found that while primary care practices are increasingly screening patients for health-related social needs, the total cost of providing evidence-based interventions far exceeds federal funding for programs designed to address them.

The Insight Partners published latest research study on “Cardiac Monitoring Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Cardiovascular Devices, Multi-Parameter ECG Monitors, Patient Monitoring Devices, Ambulatory Cardiac Monitoring, and Cardiac Monitors)

The Insight Partners published latest research study on “Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others)

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $2 million Small Business Innovative Research (“SBIR”) grant from the National Cancer Institute (“NCI”).

The Insight Partners published latest research study on “Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Global Analysis

Inhibrx, Inc. (Nasdaq: INBX) announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-101, an optimized recombinant human AAT-Fc fusion protein, for the treatment of patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).